ORAMED PHARMACEUTICALS INC. - FORM 10-K - EX-32.1 - CERTIFICATION - November 25, 2016

Attached files

file filename
EX-10.32 - AMENDMENT TO THE AMENDED AND RESTATED TECHNOLOGY LICENSE AGREEMENT, DATED JULY 24, 2016, BETWEEN HEFEI TIANHUI INCUBATOR OF TECHNOLOGIES CO., LTD., ORAMED PHARMACEUTICALS, INC. AND ORAMED LTD. - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxxii_oramed.htm
EX-10.6 - AMENDMENT, DATED JUNE 27, 2016, TO CONSULTING AGREEMENTS BY AND BETWEEN ORAMED LTD. AND KNRY, LTD., ENTERED INTO AS OF JULY 1, 2008, FOR THE SERVICES OF NADAV KIDRON. - ORAMED PHARMACEUTICALS INC.f10k2016ex10vi_oramed.htm
EX-23.1 - CONSENT OF KESSELMAN & KESSELMAN, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - ORAMED PHARMACEUTICALS INC.f10k2016ex23i_oramed.htm
EX-31.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2016ex31i_oramed.htm
EX-32.2 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2016ex32ii_oramed.htm
EX-31.2 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2016ex31ii_oramed.htm
EX-10.34 - GENERAL TECHNICAL AGREEMENT BETWEEN ORAMED LTD. AND PREMAS BIOTECH PVT. LTD., DATED JULY 24, 2016 - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxxiv_oramed.htm
EX-10.33 - SERVICE AGREEMENT, DATED AS OF JUNE 3, 2016, BETWEEN ORAMED LTD. AND XERTECS GMBH - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxxiii_oramed.htm
EX-10.31 - AMENDMENT TO THE AMENDED AND RESTATED TECHNOLOGY LICENSE AGREEMENT, DATED JUNE 3, 2016, BETWEEN HEFEI TIANHUI INCUBATOR OF TECHNOLOGIES CO., LTD., ORAMED PHARMACEUTICALS, INC. AND ORAMED LTD. - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxxi_oramed.htm
EX-10.25 - AMENDMENT TO EMPLOYMENT AGREEMENT, DATED JUNE 27, 2016, BETWEEN ORAMED LTD. AND JOSHUA HEXTER. - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxv_oramed.htm
EX-10.22 - LETTER AGREEMENT, DATED AS OF FEBRUARY 5, 2013, BETWEEN ORAMED PHARMACEUTICALS INC. AND REGALS CAPITAL LP. - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxii_oramed.htm
EX-10.7 - AMENDMENT, DATED JUNE 27, 2016, TO CONSULTING AGREEMENTS BY AND BETWEEN ORAMED LTD. AND KNRY, LTD., ENTERED INTO AS OF JULY 1, 2008, FOR THE SERVICES OF MIRIAM KIDRON. - ORAMED PHARMACEUTICALS INC.f10k2016ex10vii_oramed.htm
10-K - ANNUAL REPORT - ORAMED PHARMACEUTICALS INC.f10k2016_oramedpharma.htm

Exhibit 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

 

        In connection with the annual report of Oramed Pharmaceuticals Inc., or the Company, on Form 10-K for the period ended August 31, 2016, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Nadav Kidron, President, Chief Executive Officer and a Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:

 

 1.   The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and
   
 2.   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 24, 2016 By: /s/ Nadav Kidron
    Nadav Kidron
    President and Chief Executive Officer

 

Stock widget

Investing forum

ORAMED PHARMACEUTICALS INC. Reports